1. Market Research
  2. > Biotechnology
  3. > Genomics Proteomics and Enabling Technology Market Trends
Epigenetics Market - Global Opportunity Analysis and Industry Forecast, 2017-2023

Epigenetics Market - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • May 2017
  • 185 pages
  • ID: 5281635
  • Format: PDF
  • By Allied Market Research


Table of Contents

Epigenetics Market by Product [Enzymes (DNA Ligases, DNA Polymerases, Other DNA-modifying Enzymes), Kits & Assays (Bisulfite Conversion Kits, Chip-Seq Kits, Deep Sequencing Kits, Methyltransferase Assays, Histone Assays, Immunoprecipitation Kits), Instruments (Mass Spectrometers, Next-generation Sequencers, qPCRs, and Sonicators), and Reagents (Antibodies, Buffers, Histones, Magnetic Beads, Primers, and Other Epigenetics Reagents)], Application (Oncology and Non-oncology Diseases, Developmental Biology, Drug Discovery, and Others), and End User [Academic & Research Institutes, Pharmaceutical Companies, Biotechnology Companies, and Contract Research Organizations (CROs)] - Global Opportunity Analysis and Industry Forecast, 2017-2023

Epigenetics is a stream of genetics that involves the study of cellular and physiological trait variations initiated by external or ecological aspects, which turn genes on and off and affect the cellular ability to read genes without being affected by changes in the genotype Epigenetics results into changes in the organisms’ phenotype rather than the genotype, wherein the underlying DNA or RNA sequence remains unchanged. The global epigenetics market accounted for $555 million in 2016, and is estimated to reach at $1,321 million by 2023, registering a CAGR of 13.1% from 2017 to 2023.

Epigenetic alterations are essential for development; they are dynamic and change with respect to the environmental stimuli. However, these changes can also be stable and could be passed on from one generation to another. Biology and genetic expressions of most organisms are affected by epigenetics, thereby making it one of the most crucial fields of developmental genetics and molecular biology.

High incidence of cancer; increase in R&D activities; surge in investments funding, rise in epigenetic applications for non-oncology diseases; and growth in partnership between academic, pharmaceutical, and biotechnology companies cumulatively supplement the growth of the global epigenetics market. However, high cost of instruments and lack of trained professionals impede the growth of this market. Furthermore, untapped potential of emerging markets provides lucrative opportunities to the market players.

The epigenetics market is segmented based on product, application, end user, and geography. Based on product, it is divided into enzymes, kits & assays, instruments, and reagents.

Enzymes are further classified into DNA ligases, DNA polymerases, other DNA-modifying enzymes, acetylases, methyltransferases, other protein-modifying enzymes, reverse transcriptase, RNA ligases, and other RNA-modifying enzymes. Kits & assays are further subdivided into bisulfite conversion kits, chip-seq kits, deep sequencing kits, methyltransferase assays, histone assays, immunoprecipitation kits & other epigenetic kits. Based on instruments, the market is further sub segmented into mass spectrometers, next-generation sequencers, qPCRs, and sonicators & other instruments. Reagents are further divided into antibodies, buffers, histones, magnetic beads, primers, and other epigenetics reagents.

On the basis application, the market is classified into oncology and non-oncology. Oncology is further sub segmented into solid tumors & liquid tumors.

Non-oncology applications include inflammatory diseases, metabolic diseases, infectious diseases, cardiovascular diseases, developmental biology, drug discovery, and other applications. On the basis of end user, the market is classified into academic & research institutes, pharmaceutical companies, biotechnology companies, and contract research organizations (CROs). Geographically, it is analyzed based on four regions, namely, North America, Europe, Asia-Pacific, and LAMEA.

The study provides an in-depth analysis of the global epigenetics market and the current trends and future estimations to elucidate the imminent investment pockets.
It presents a quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the market based on application assists to understand the trends in the industry.
Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

Abcam plc.
Epizyme, Inc.
New England Biolabs, Inc.
Merck & Co.,
Thermo Fisher Scientific, Inc.
Active Motif,
Diagenode, Inc.
Zymo Research Corporation


By Product
DNA Ligases
DNA Polymerases
Other DNA-modifying Enzymes
Other Protein-modifying Enzymes
Reverse Transcriptase
RNA Ligases
Other RNA-modifying Enzymes
Kits & Assays
Bisulfite Conversion Kits
Chip-seq Kits
Deep Sequencing Kits
Methyltransferase Assays
Histone Assays
Immunoprecipitation Kits
Other Epigenetic Kits
Mass Spectrometers
Next-generation Sequencers
Other Instruments
Magnetic Beads
Other Epigenetics Reagents

By Application
Solid Tumors
Liquid Tumors
Inflammatory Diseases
Metabolic Diseases
Infectious Diseases
Cardiovascular Diseases
Developmental Biology
Drug Discovery

By End User
Academic & Research Institutes
Pharmaceutical Companies
Biotechnology Companies
Contract Research Organizations (CROs)

By Geography
North America
Rest of Europe
South Korea
Rest of Asia-Pacific
Saudi Arabia
South Africa
Rest of LAMEA

The other players in the value chain include (profiles not included in the report)
CellCentric Ltd.
Chroma Therapeutics Ltd.
Eisai Co. Ltd.
Novartis International AG
Oncolys Biopharma Inc.
Syndax Pharmaceuticals, Inc.
Valirx plc.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Hemophilia A - Pipeline Review, H2 2019

Hemophilia A - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Hemophilia A - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A - Pipeline Review, H2 2019, provides an overview of the Hemophilia A (Hematology ...

Wounds - Pipeline Review, H2 2019

Wounds - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Wounds - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Wounds - Pipeline Review, H2 2019, provides an overview of the Wounds (Dermatology) pipeline landscape.Wound ...

Human Cytomegalovirus Envelope Glycoprotein B - Pipeline Review, H2 2019

Human Cytomegalovirus Envelope Glycoprotein B - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Human Cytomegalovirus Envelope Glycoprotein B - Pipeline Review, H2 2019SummaryHuman Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 9 molecules. Out of which approximately ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on